Antidotes
-
Subject Areas on Research
- A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
- A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
- A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
- A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.
- Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
- Advances in Stroke 2017.
- Ameliorating the developmental neurotoxicity of chlorpyrifos: a mechanisms-based approach in PC12 cells.
- Antidote control of aptamer therapeutics: the road to a safer class of drug agents.
- Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor.
- Antidote-mediated control of an anticoagulant aptamer in vivo.
- Applications and future of aptamers that achieve rapid-onset anticoagulation.
- Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State.
- Aptamers: an emerging class of therapeutics.
- Conventional and Unconventional Lifesaving Therapies in an Adolescent With Amlodipine Ingestion.
- Development of universal antidotes to control aptamer activity.
- Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
- Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors.
- Emerging applications of aptamers for anticoagulation and hemostasis.
- Endotracheal administration of flumazenil.
- Endotracheal flumazenil: a new route of administration for benzodiazepine antagonism.
- First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
- Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.
- In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
- Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
- Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.
- Methylene blue in congenital methemoglobinemia: prophylactic or on demand?
- Paradoxical reactions in children associated with midazolam use during endoscopy.
- Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
- Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
- Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.
- Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.
- RNA aptamers as reversible antagonists of coagulation factor IXa.
- Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.
- Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor.
- Regulatable aptamers in medicine: focus on antithrombotic strategies.
- Reversal agents for non-vitamin K antagonist oral anticoagulants.
- Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage.
- Reversing targeted oral anticoagulants.
- Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
- Sulfidation of silver nanoparticles: natural antidote to their toxicity.
- Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.
- Therapeutic aptamers and antidotes: a novel approach to safer drug design.
- Toxic effects of chlorine gas and potential treatments: a literature review.
- When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.
- Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?